Glenmark Pharmaceuticals Ltd. (GLENMARK) Share Price Rises 3.42% as Large-Cap Stock Clears Threshold
- August 20, 2026
- Posted by: Harsh Piplani
- Category: News
Glenmark Pharmaceuticals Ltd. traded at Rs 2,332.05, up 3.42% today, taking its market capitalisation to Rs 65,143.1 crore and placing it among notable large-cap gainers.
Glenmark Pharmaceuticals Ltd. Share Price moved to Rs 2,332.05 on 20 August 2026, up Rs 77.05 or 3.42% from the previous close of Rs 2,255, lifting the company’s market capitalisation to Rs 65,143.1 crore. In Stock Market Today trade, that made the healthcare name a notable top gainer and a clear event-led entry in Glenmark Pharmaceuticals Ltd. Stock News.
The move matters because this was not just a routine uptick. With the day’s high at Rs 2,341.55 and the low at Rs 2,255, the session reflected a steady price rise from near the previous close toward the upper end of the intraday range. The supplied data confirms the price event, though it does not establish a company-specific catalyst behind why the stock is rising today.
For investors tracking Glenmark Pharmaceuticals Ltd. Share Price Today, the key points are straightforward. The stock opened at Rs 2,255.95, stayed above the day’s low of Rs 2,255, and added momentum through the session. Total traded volume stood at 4,49,214 shares across exchanges, including 4,15,009 shares on NSE and 34,205 shares on BSE, with reported turnover of Rs 7.98 crore. Univest notes that such a move in a company of this size naturally attracts attention because large-cap price rises above threshold levels tend to stand out in Share Market Today screens, market movers lists and intraday stock updates.
Glenmark Pharmaceuticals Ltd. (GLENMARK) Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 2,332.05 |
| Previous Close | Rs 2,255 |
| Today's Change | +Rs 77.05 (+3.42%) |
| Day Open | Rs 2,255.95 |
| Day High | Rs 2,341.55 |
| Day Low | Rs 2,255 |
| Current Volume (BSE) | 34,205 |
| BSE Traded Volume | 34,205 |
| NSE Traded Volume | 4,15,009 |
| Combined NSE + BSE Volume | 4,49,214 |
| Turnover | Rs 7.98 crore |
| Market Capitalisation | Rs 65,143.1 crore |
| Market Cap Category | Large Cap |
Glenmark Pharmaceuticals Ltd. (GLENMARK) traded at Rs 2,332.05. versus the previous close of Rs 2,255, a rise of 3.42%. The stock opened at Rs 2,255.95, reached Rs 2,341.55, touched Rs 2,255. Reported volume was 34,205.
Glenmark Pharmaceuticals Ltd. (GLENMARK) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 65,143.1 crore |
Today’s move sits inside a large listed business rather than a thinly traded small counter. Glenmark Pharmaceuticals Ltd. carries a market capitalisation of Rs 65,143.1 crore, and that scale itself adds context to the share price rise because large-cap stocks typically need broader market participation to clear a 3% threshold in a single session.
From a fundamental-analysis standpoint, market capitalisation is a size indicator, not a quality verdict, but it still matters. A company valued at Rs 65,143.1 crore usually receives closer institutional tracking, wider market visibility and faster placement into daily market news discussions than a very small stock. In Glenmark Pharmaceuticals Ltd. Share Price Today coverage, that scale helps explain why the move is being watched across both NSE and BSE screens.
The supplied data does not frame this event around earnings, margins, leverage or cash generation. What it does confirm is that the market is currently assigning a large valuation footprint to the company within the listed healthcare space. For investors reading Glenmark Pharmaceuticals Ltd. Stock Analysis, that means the event should be viewed through two lenses: first, the significance of a 3.42% gain in a large-cap stock; second, the need to place that gain in broader sector and peer context rather than reading the price action in isolation.
Univest’s approach in such cases is to keep the interpretation disciplined. A same-day price rise can highlight market attention, but its importance grows when measured against the company’s size, trading activity and sector position. Here, the size is undeniably substantial. That is why the next useful step is to compare Glenmark Pharmaceuticals Ltd. with the wider Healthcare benchmark and with supplied listed peers, using only verified numbers rather than speculation.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Benchmark Scope | same sector |
| Benchmark Median P/E | 26.32x |
| Benchmark Average P/E | 61.3x |
| Benchmark P/E Range | 2.76x to 1,607.56x |
| Benchmark Median P/B | 1.9x |
| Benchmark Median ROE | 11.12% |
| Benchmark Median ROCE | 13.35% |
| Company Market Capitalisation | Rs 65,143.1 crore |
| Benchmark Median Market Cap | Rs 135.91 crore |
Glenmark Pharmaceuticals Ltd. (GLENMARK) is classified under sector: Healthcare.
Track today’s top gainers through the Univest top gainers screener. The peer table below provides the company-level comparison.
Glenmark Pharmaceuticals Ltd. operates in the Healthcare sector, and the supplied benchmark shows a broad listed universe of 196 companies. That matters because today’s move should not be read only as isolated price action; it should also be viewed against the valuation and profitability backdrop of the same sector.
The sector snapshot covers 196 companies in the same sector. Within that benchmark, the median P/E stands at 26.32 and the average P/E at 61.3, based on 157 companies. The range is unusually wide, stretching from 2.76 to 1,607.56, which signals that valuation dispersion inside Healthcare is significant. For price-to-book, 195 companies were counted, with a median of 1.9, an average of 2.61 and a range from -13.33 to 16.47.
Profitability markers also show a broad spread. Median ROE in the sector is 11.12%, while average ROE is 15.66% across 195 companies. Median ROCE is 13.35% and average ROCE is 17.87%, again based on 195 companies. The benchmark’s market-cap distribution highlights just how large Glenmark Pharmaceuticals Ltd. is in comparison with the sector’s broader listed population: the median market capitalisation is Rs 135.91 crore, the average is Rs 467.67 crore, the minimum is Rs 3.67 crore and the maximum within this snapshot is Rs 3,012.78 crore.
Against that backdrop, Glenmark Pharmaceuticals Ltd.’s market capitalisation of Rs 65,143.1 crore stands far above the benchmark’s median, average and even the reported maximum company market cap in the supplied sector basket. That does not, by itself, establish valuation richness or cheapness, but it clearly places the company in a very different scale bracket from the typical Healthcare constituent represented here. Univest therefore sees the stock’s 3.42% rise as especially relevant because it occurred in a company whose market footprint is much larger than the benchmark sample’s central tendency.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Ind-Swift Laboratories Ltd. | INDSWFTLAB | 3,012.78 | 48.9 | 1.87 | -0.78 | 8.31 |
| Hikal Ltd. | HIKAL | 2,679.94 | 0 | 2.22 | 15.22 | 16.15 |
| Dishman Carbogen Amcis Ltd. | DCAL | 2,648.85 | 167.12 | 0.41 | -2.89 | -0.26 |
| Solara Active Pharma Sciences Ltd. | SOLARA | 2,641.96 | 0 | 2.08 | 17.23 | 15.34 |
| Beta Drugs Ltd. | BETA | 2,610.72 | 64.32 | 10.17 | 18.65 | 22.17 |
Glenmark Pharmaceuticals Ltd. (GLENMARK) has a market capitalisation of Rs 65,143.1 crore. Among the 5 peers shown, 0 have a larger market capitalisation.
The supplied peer set gives a useful reference point for Glenmark Pharmaceuticals Ltd. Share Price because it places today’s move beside other listed Healthcare names. Even without company-specific valuation ratios in the dataset, the peer numbers still show how distinct Glenmark’s scale is relative to this basket.
Glenmark Pharmaceuticals Ltd. has a market capitalisation of Rs 65,143.1 crore. By contrast, the listed peers in the supplied snapshot range from Rs 2,386.28 crore for Fredun Pharmaceuticals Ltd. to Rs 3,012.78 crore for Ind-Swift Laboratories Ltd. Hikal Ltd. stands at Rs 2,679.94 crore, Dishman Carbogen Amcis Ltd. at Rs 2,648.85 crore, Solara Active Pharma Sciences Ltd. at Rs 2,641.96 crore and Beta Drugs Ltd. at Rs 2,610.72 crore. Dr Agarwals Eye Hospital Ltd. is at Rs 2,569.06 crore, while Venus Remedies Ltd. is at Rs 2,417.29 crore.
That means Glenmark Pharmaceuticals Ltd. is operating at a scale many times larger than every peer listed in this table. The peer group’s valuation and profitability readings also show how mixed the Healthcare landscape can be. Ind-Swift Laboratories trades at a P/E of 48.9 with ROE of -0.78% and ROCE of 8.31%. Dishman Carbogen Amcis shows a P/E of 167.12 with ROE of -2.89% and ROCE of -0.26%. Beta Drugs carries a P/E of 64.32, P/B of 10.17, ROE of 18.65% and ROCE of 22.17%. Venus Remedies trades at a P/E of 20.4 with ROE of 9.85% and ROCE of 7.89%.
For investors following Glenmark Pharmaceuticals Ltd. Share Price Update, the practical takeaway is that today’s rise happened in a company whose market cap sits in a different league from the supplied peers. Univest reads that as a scale advantage in market attention terms, while leaving valuation and profitability judgments tied strictly to the figures available in the peer and sector datasets.
Why Investors Are Watching Glenmark Pharmaceuticals Ltd.
Glenmark Pharmaceuticals Ltd. Share Price is being watched because the stock has posted a verified same-day price rise large enough to cross its category threshold, and it has done so in a company with a market capitalisation that stands well above the sector sample and the listed peer basket supplied here.
- Verified price action: The stock rose Rs 77.05, or 3.42%, from Rs 2,255 to Rs 2,332.05.
- Intraday strength: It opened at Rs 2,255.95, touched a high of Rs 2,341.55 and held near that zone.
- Category relevance:<
- Trading activity: Total volume reached 4,49,214 shares, including 4,15,009 on NSE and 34,205 on BSE, with turnover of Rs 7.98 crore.
- Scale context: Market capitalisation at Rs 65,143.1 crore is far above the sector benchmark median and average.
- Sector position: The move comes within a Healthcare universe where valuation and profitability ranges are very wide.
What investors may monitor next is whether Glenmark Pharmaceuticals Ltd. Share Price continues to hold closer to the day’s high than the previous close, whether trading participation remains elevated in subsequent sessions, and how the stock behaves relative to the broader Healthcare space. Univest also sees sector and peer context as essential, because a top gainer move in a large-cap name often gets interpreted differently from a similar percentage change in a much smaller company.
About Glenmark Pharmaceuticals Ltd.
Glenmark Pharmaceuticals Ltd. is represented in the supplied data as a Healthcare sector company listed under the symbol GLENMARK. In market discussions, that places it within one of the most closely tracked segments of the Indian stock market, where investors often compare size, market position and trading performance across a wide mix of healthcare-related businesses.
The wider sector snapshot supplied with this article includes companies from Pharmaceuticals & Drugs as well as Hospital & Healthcare Services, illustrating how broad the Healthcare classification can be in listed-market analysis. Within that framework, Glenmark Pharmaceuticals Ltd. stands out primarily on scale, with a market capitalisation of Rs 65,143.1 crore. That is materially higher than the central market-cap levels captured in the sector benchmark and much larger than the supplied peer basket.
For readers coming through Glenmark Pharmaceuticals Ltd. Latest News or Glenmark Pharmaceuticals Ltd. Company News searches, the most useful company-level takeaway from the verified dataset is not a narrative claim about operations but a market-based one: this is a large-cap healthcare stock whose movements carry weight in daily market screens. That is why today’s share price rise has drawn attention on Univest and why Glenmark Pharmaceuticals Ltd. Share Price News is likely to remain active as investors continue to track its stock performance, market capitalisation and position within the healthcare universe.
Track Glenmark Pharmaceuticals Ltd. Share Price on Univest
Use Glenmark Pharmaceuticals Ltd. (GLENMARK) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top gainers lists and related market analysis.
Investors who want a structured view of Glenmark Pharmaceuticals Ltd. Share Price can track it on Univest through live market updates, daily stock performance moves and deeper context around market capitalisation, sector standing and peer comparison. Univest also helps users follow Glenmark Pharmaceuticals Ltd. Share Price Today alongside 52-week levels, technical indicators when available, fundamental ratios when available and shareholding pattern disclosures when available in the data flow.
For active market participants, that makes Univest useful not only for Glenmark Pharmaceuticals Ltd. Stock News but also for comparing price action across NSE and BSE, reviewing market movers and keeping an eye on Stocks in News without losing sight of benchmark context. In a session like this, where a large-cap stock has cleared its event threshold, a platform view can help separate simple price movement from broader market significance.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What is Glenmark Pharmaceuticals Ltd. Share Price today?
Ans. Glenmark Pharmaceuticals Ltd. Share Price was Rs 2,332.05 at the time of this update. The stock was up Rs 77.05 from the previous close of Rs 2,255, translating into a 3.42% gain for the session.
Why is Glenmark Pharmaceuticals Ltd. rising today?
Ans. The supplied data confirms that the stock rose 3. However, the verified dataset establishes the price event rather than a company-specific catalyst for the move.
How much did Glenmark Pharmaceuticals Ltd. stock gain today?
Ans. Glenmark Pharmaceuticals Ltd. stock gained Rs 77.05 on the day. That took the share price from the previous close of Rs 2,255 to Rs 2,332.05, which works out to a same-day rise of 3.42%.
What were the day high and day low for Glenmark Pharmaceuticals Ltd.?
Ans. The stock traded between Rs 2,255 and Rs 2,341.55 during the session. It opened at Rs 2,255.95, touched the day high at Rs 2,341.55 and held much of the gain while trading at Rs 2,332.05.
Did Glenmark Pharmaceuticals Ltd. clear its market-cap threshold today?
Ans. Yes. Glenmark Pharmaceuticals Ltd. Today’s 3.42% share price gain moved the stock above that exact event threshold.
What is the market capitalisation of Glenmark Pharmaceuticals Ltd.?
Ans. Glenmark Pharmaceuticals Ltd. had a market capitalisation of Rs 65,143.1 crore in the supplied dataset. That size is far above the Healthcare sector benchmark median of Rs 135.91 crore and average of Rs 467.67 crore.
How much volume was traded in Glenmark Pharmaceuticals Ltd. today?
Ans. Total traded volume stood at 4,49,214 shares. Of this, 4,15,009 shares were traded on NSE and 34,205 shares on BSE, while the reported turnover for the session was Rs 7.98 crore.
How does Glenmark Pharmaceuticals Ltd. compare with the Healthcare sector on size?
Ans. On market capitalisation, Glenmark Pharmaceuticals Ltd. is much larger than the broad Healthcare benchmark in the supplied data. Its Rs 65,143.1 crore market cap stands above the benchmark median, average and reported maximum company value.
How does Glenmark Pharmaceuticals Ltd. compare with the supplied peers?
Ans. Glenmark Pharmaceuticals Ltd. is far larger than every company in the supplied peer basket. The peers range from Rs 2,386.28 crore to Rs 3,012.78 crore in market cap, versus Glenmark’s Rs 65,143.1 crore valuation.
Where can investors track Glenmark Pharmaceuticals Ltd. Share Price updates?
Ans. Investors can track Glenmark Pharmaceuticals Ltd. Share Price on Univest for live price movement, market-cap context, sector comparisons and stock performance monitoring. That helps place daily moves like today’s 3.42% rise in a broader analytical framework.
